Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article
about
Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme TreatmentNeurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment.Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.Therapeutic strategies to improve drug delivery across the blood-brain barrier.Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Real-time hemodynamic response and mitochondrial function changes with intracarotid mannitol injectionCharting the course across the blood-brain barrierIntra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survivalRevisiting intra-arterial drug delivery for treating brain diseases or is it "déjà-vu, all over again"?Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres.Sufficient virus-neutralizing antibody in the central nerve system improves the survival of rabid rats.Vascular distribution of glioblastoma multiforme at diagnosisDelivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Monitoring the Response of Hyperbilirubinemia in the Mouse Brain by In Vivo Bioluminescence Imaging.Intra-arterial chemotherapy for malignant gliomas: a critical analysis.Ependymoma in children: molecular considerations and therapeutic insights.Reporting standards for endovascular chemotherapy of head, neck and CNS tumors.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.Endovascular superselective treatment of brain tumors: a new endovascular era? A quick review.Emerging insights into barriers to effective brain tumor therapeutics.Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it.Strategies for transporting nanoparticles across the blood-brain barrier.Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier.Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.Targeting brain tumors by intra-arterial delivery of cell-penetrating peptides: a novel approach for primary and metastatic brain malignancy.Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas.Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.Trends in Malignant Glioma Monoclonal Antibody Therapy.Glioblastoma Treatments: An Account of Recent Industrial DevelopmentsContemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma MultiformeGlioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
P2860
Q26773083-65C6AD1D-7C79-4B7B-87C3-2EA58B17CDD3Q26801485-1B9E1029-F998-4354-9D74-AC1AE0ECC243Q27010580-26E8C0E6-E4C4-4BFE-940A-B7DC1914AEFAQ28539271-81ED7971-16D9-4C55-835B-C4505EFD0E16Q30385033-46E56993-F3DA-463A-B608-1E3922F9C02AQ30407443-C195ECA9-2B75-46F7-8BE2-D22FD552A0A9Q30454047-CA31FF38-D5DF-4511-AFCA-159378920A52Q30616602-98AF7304-E14B-4F7B-AC11-8C37B8C52923Q33670175-7FE677F8-13A5-4AF8-A07A-23461D2BC8F8Q33779922-7BB7EBB6-6A8C-462C-8860-99C9D6DC0719Q34260206-675ABBB9-8797-401C-9ADE-9E5F878A7DB8Q34609094-42E0A157-C2C2-4B92-9953-6503C86E5362Q34943946-CE8AC68F-7EE9-4252-BCF8-47CC1465D0B3Q35067752-F27BD6C2-6B7D-44FE-8AD0-8C3BECC680A8Q36200661-802C71B2-4CC5-4710-9D8F-F924509A3AD7Q36696392-75FE9C06-A463-4EDC-BC2D-B8551F27E5B5Q37308322-3BE0C9C6-982F-4A3B-9044-BB19F27557C0Q37631453-D555C461-602C-485D-A50A-55052A8B9BA9Q37946674-B1C08373-F3DB-4A1D-924C-897B3044560FQ38101501-A2850AFA-CD98-40FA-9454-5061AD6B1918Q38119427-13B4AD56-8373-4598-A49D-9098FC3EF771Q38179019-D4886129-4C72-43D2-A4B8-E57772E65643Q38186612-EBFB3013-EDA2-4B70-93C2-517CA194CDC5Q38237653-EB5721A6-13A2-4A12-AE91-1A83A9875608Q38537217-1EAE97F5-3091-411A-8FE9-9679EB744FD7Q38626364-1DA3387A-2CD0-4E92-9D26-32E154EA4704Q38662677-E97E7541-CFEA-4B6B-9173-24F4DD35A1C7Q38975707-826B04E7-CD63-44F6-97FE-A1CEC018E0A1Q39139224-D5240C71-D555-4C88-AEF2-8E3FCDA47C77Q48125769-69E3F117-9625-40A8-AE2E-644D044EB1B4Q48220641-024A2D2E-C2D0-4C6E-88F5-2E67E9637C39Q48245198-DCF08C9A-6314-4BF0-92B8-66AC7D56BE8FQ48519374-E6CF5E34-6C9E-49DF-9D02-3C8A3C95B118Q48541574-ACF415A4-2AF5-4D4A-BF1E-83C9E33EEB46Q48858178-D71626F9-190A-4838-AB6A-B700E81CD2D6Q54942652-AA12010A-46D2-47B7-941B-63BF902229B3Q57111067-A4BBDC17-A1B0-4AD7-9010-C925C6642005Q57141680-5BF26EF4-C79C-43D6-95C3-B91AD94BD792Q59134092-9DBC30F1-BA99-4BC5-86A5-6F5FD0F41610
P2860
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@ast
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@en
type
label
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@ast
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@en
prefLabel
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@ast
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@en
P2093
P2860
P356
P1476
Safety and maximum tolerated d ...... gnant glioma. Clinical article
@en
P2093
Apostolos J Tsiouris
Christoph P Hofstetter
Howard A Riina
Ilhami Kovanlikaya
Jared Knopman
John A Boockvar
Kartik Kesavabhotla
Paul Christos
Philip Stieg
Robert D Zimmerman
P2860
P304
P356
10.3171/2010.9.JNS101223
P577
2010-10-22T00:00:00Z